ArticleAlzheimer's research & therapy2021
CERT
Open access · goldAbstract read
In one paragraph
Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- GPBP or CERT: The Roles in Autoimmunity, Cancer or Neurodegenerative Disease-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Plasma ceramide mediates the association of peripheral T cells with Alzheimer's disease.Journal of advanced research · 2026Article
- Olfactory cleft biopsy analysis of Alzheimer's disease pathobiology across disease stages.Nature communications · 2026Article
- Sphingolipids in Emotional Well-Being.Journal of neurochemistry · 2026Review
- Exploring Ceramide C16:0 as a Novel Biomarker and Therapeutic Target for Atherosclerosis.Journal of the American Heart Association · 2026Review
- The physiological and pathological effects of sphingolipid metabolism and signaling in the central nervous system.Brain pathology (Zurich, Switzerland) · 2026Review
- Exploring ceramide as a novel biomarker and therapeutic target for Alzheimer's disease.Frontiers in neuroscience · 2026Review
- Olfactory biopsy analysis of Alzheimer's pathobiology across disease stages.bioRxiv : the preprint server for biology · 2025Article
- Individual lipid alterations at the origin of neuronal Ceramide Synthase defects.PLoS genetics · 2025Article
- Obesity promotes ARDS by modulating ceramide transfer protein-ceramide pathway and exacerbating oxidative stress/apoptosis in alveolar macrophages.Cellular and molecular life sciences : CMLS · 2025Article
- Targeting ceramide transfer protein sensitizes AML to FLT3 inhibitors via a GRP78-ATF6-CHOP axis.Nature communications · 2025Article
- Neurotensin-neurotensin receptor 2 signaling in adipocytes suppresses food intake through regulating ceramide metabolism.Cell research · 2025Article
- Lipidomics of Huntington's Disease: A Comprehensive Review of Current Status and Future Directions.Metabolites · 2025Review
- Lipid-nanoparticle-induced vacuolization in microglia.Communications biology · 2024Article
- Article
- Regulation of cellular and systemic sphingolipid homeostasis.Nature reviews. Molecular cell biology · 2024Review
- Abnormal Regulation of Mitochondrial Sphingolipids during Aging and Alzheimer's Disease.ASN neuro · 2024Article
- Novel cuproptosis metabolism-related molecular clusters and diagnostic signature for Alzheimer's disease.Frontiers in molecular biosciences · 2024Article
- A review of the mechanisms of abnormal ceramide metabolism in type 2 diabetes mellitus, Alzheimer's disease, and their co-morbidities.Frontiers in pharmacology · 2024Review
- Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 12 institutions in 6 countries.
Simone M Crivelli *Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, the Netherlands.
Qian Luo *Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, the Netherlands.
Jo A A StevensDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, the Netherlands.
Caterina GiovagnoniDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, the Netherlands.
Daan van KruiningDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, the Netherlands.
Gerard BodeDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, the Netherlands.
Sandra den HoedtDepartment of Internal Medicine, Laboratory Vascular Medicine, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Barbara HoboLaboratory for Neuroregeneration, Netherlands institute for Neuroscience, Amsterdam, the Netherlands.
Anna-Lena ScheithauerDepartment of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Jochen WalterDepartment of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Monique T MulderDepartment of Internal Medicine, Laboratory Vascular Medicine, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Christopher ExleyThe Birchall Centre, Lennard-Jones Laboratories, Keele University, Staffordshire, UK.
Matthew MoldThe Birchall Centre, Lennard-Jones Laboratories, Keele University, Staffordshire, UK.
Michelle M MielkeDivision of Epidemiology, Department of Health Science Research, and Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA.
Helga E De VriesDepartment of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands.
Kristiaan WoutersDepartment of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.
Daniel L A van den HoveDepartment of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany.
Dusan BerkesDepartment of Organic Chemistry, Slovak University of Technology, Radlinského 9, 81237, Bratislava, Slovak Republic.
María Dolores LedesmaDepartment of Molecular Neuropathology, Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.
Joost VerhaagenLaboratory for Neuroregeneration, Netherlands institute for Neuroscience, Amsterdam, the Netherlands.
Mario LosenDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, the Netherlands.
Erhard BieberichDepartment of Physiology, University of Kentucky College of Medicine, Lexington, KY, USA.
Pilar Martinez-MartinezDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, the Netherlands. p.martinez@maastrichtuniversity.nl.ORCID 0000-0002-5990-3373
Maastricht University · NLErasmus MC · NLKeele University · GBNetherlands Institute for Neuroscience · NLUniversity of Bonn · DEUniversity of Kentucky · USAmsterdam Neuroscience · NLCentro de Biología Molecular Severo Ochoa · ESMaastricht University Medical Centre · NLMayo Clinic in Florida · USSlovak University of Technology in Bratislava · SKUniversity of Würzburg · DE
Funding
Function of ceramide in neurodegenerative diseaseR01AG034389 · NIA · UNIVERSITY OF KENTUCKY · PI BIEBERICH, ERHARD · 2010 to 2020
$3.6MRegulation of Microglial Activation State by a Lipid TransporterR01AG064234 · NIA · UNIVERSITY OF KENTUCKY · PI BIEBERICH, ERHARD · 2020 to 2024
$1.9MSphingolipids and Inflammation in the Development and Progression of Alzheimer'sR01AG049704 · NIA · MAYO CLINIC ROCHESTER · PI MIELKE, MICHELLE M · 2015 to 2018
$1.5MRegulation of cilia by ceramideR01NS095215 · NINDS · UNIVERSITY OF KENTUCKY · PI BIEBERICH, ERHARD · 2016 to 2019
$1.4MRegulation of microglial activation state in neurodegenerationR56AG064234 · NIA · UNIVERSITY OF KENTUCKY · PI BIEBERICH, ERHARD · 2019 to 2019
$375kTBI-induced exosome release accelerates Alzheimer's disease pathologyI01BX003643 · VA · VA MEDICAL CENTER - LEXINGTON, KY · PI BIEBERICH, ERHARD · 2020 to 2023
–BLRD VA I01 BX003643NIA NIH HHS R01 AG034389NIA NIH HHS R01 AG049704NIA NIH HHS R01 AG064234NIH HHS R01AG034389NIH HHS R01AG049704NIH HHS R01NS095215NIH HHS R56AG064234NINDS NIH HHS R01 NS095215U.S. Department of Veterans Affairs I01BX003643
Abstract
backgroundDysregulation of ceramide and sphingomyelin levels have been suggested to contribute to the pathogenesis of Alzheimer's disease (AD). Ceramide transfer proteins (CERTs) are ceramide carriers which are crucial for ceramide and sphingomyelin balance in cells. Extracellular forms of CERTs co-localize with amyloid-β (Aβ) plaques in AD brains. To date, the significance of these observations for the pathophysiology of AD remains uncertain.
methodsA plasmid expressing CERT
resultsHere, we report that CERT
conclusionOur results demonstrate a crucial role of CERT
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBrainCeramidesDisease Models, AnimalInflammationMaleMiceMice, TransgenicPlaque, AmyloidAmyloid beta-PeptidesAmyloid beta-Protein PrecursorCeramides5xFADAdeno-associated virus (AAV)Alzheimer’s disease (AD)Amyloid-β plaquesCeramideCeramide transporter protein (CERT)MicrogliaNeuroinflammationSphingomyelin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.